Analyst Price Targets — EMBC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 23, 2025 11:21 am | Marie Thibault | BTIG | $25.00 | $10.72 | TheFly | Embecta price target lowered to $25 from $26 at BTIG |
| December 2, 2024 11:18 am | Kallum Titchmarsh | Morgan Stanley | $20.00 | $20.68 | StreetInsider | Morgan Stanley Upgrades Embecta (EMBC) to Overweight |
| November 27, 2024 11:05 am | Marie Thibault | BTIG | $26.00 | $19.80 | StreetInsider | BTIG Upgrades Embecta (EMBC) to Buy |
| July 15, 2024 8:03 am | Kallum Titchmarsh | Morgan Stanley | $12.00 | $13.17 | TheFly | Embecta price target lowered to $12 from $16 at Morgan Stanley |
| August 16, 2022 7:51 am | — | Morgan Stanley | $36.00 | $33.42 | Benzinga | Morgan Stanley Maintains Equal-Weight on Embecta, Raises Price Target to $36 |
Latest News for EMBC
PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the “Board”) of embecta has elected Devdatt “Dev” Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective…
Despite an 8.2% forward yield, be careful with Perrigo, due to its value trap reputation. Yielding 6.7%, Pfizer is a strong choice among high-yield dividend stocks, given the company's post-COVID-19 catalysts.
Shares of Embecta Corp. (NASDAQ: EMBC - Get Free Report) gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $11.35, but opened at $12.61. Embecta shares last traded at $11.34, with a volume of 254,893 shares traded. The company reported $0.71 earnings
Embecta Corp. (EMBC) Q1 2026 Earnings Call Transcript
PARSIPPANY, N.J., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today reported first quarter fiscal 2026 financial results.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.